NCT00518739View on ClinicalTrials.gov

MK2461 in Patients With Advanced Cancer (2461-001)(COMPLETED)

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Advanced Cancer
Interventions
DRUG

MK2461

Patients will be administered oral MK2461 twice daily and will be treated for 28 day cycles. Patients will be enrolled in cohorts and will be treated at sequentially rising dose levels of MK2461. 60 mg dry filled capsules, escalating to 240 mg ( for dosing in Cohort 4 \& beyond).

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00518739 - MK2461 in Patients With Advanced Cancer (2461-001)(COMPLETED) | Biotech Hunter | Biotech Hunter